insiderwall
Menu
SuperinvestorInsider
Lineage Cell Therapeutics Inc. LCTX

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel allogeneic, or off‑the‑shelf, cell therapies for serious neurological and ophthalmic conditions. The company leverages a proprietary cell-based technology platform and in-house development and manufacturing capabilities

SectorHealthcare
ExchangeNYSE
IndustryBiotechnology
CountryUnited States
Employees70
TickerLCTX

Statistics

Market Cap$306.6M
Revenue (TTM)$14.6M
Net Income-$63.5M
Net Margin-436.5%
EPS$-0.28
P/E-4.55
P/S20.75
P/B5.69
EV/EBITDA-11.49
ROE-98.2%
Dividend Yield
Price$1.23

Data: Twelve Data · Revenue = mcap / P/S